|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-2-17
|
|
pubmed:abstractText |
Bortezomib, a boronic acid dipeptide, has been recently introduced as a new approach to treating multiple myeloma (MM). The goal of this work was to evaluate the added value of patient-reported outcomes (PRO) in the interpretation of bortezomib clinical trial outcomes.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
976-82
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16432077-Adult,
pubmed-meshheading:16432077-Aged,
pubmed-meshheading:16432077-Antineoplastic Agents,
pubmed-meshheading:16432077-Boronic Acids,
pubmed-meshheading:16432077-Europe,
pubmed-meshheading:16432077-Female,
pubmed-meshheading:16432077-Humans,
pubmed-meshheading:16432077-Male,
pubmed-meshheading:16432077-Middle Aged,
pubmed-meshheading:16432077-Multiple Myeloma,
pubmed-meshheading:16432077-Patient Satisfaction,
pubmed-meshheading:16432077-Predictive Value of Tests,
pubmed-meshheading:16432077-Prognosis,
pubmed-meshheading:16432077-Pyrazines,
pubmed-meshheading:16432077-Quality of Life,
pubmed-meshheading:16432077-Questionnaires,
pubmed-meshheading:16432077-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.
|
|
pubmed:affiliation |
Johnson & Johnson Pharmaceutical Services and Pharmaceutical Research and Development, Beerse, Belgium. ddubois@psmbe.jnj.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
